281 related articles for article (PubMed ID: 29471776)
1. T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology.
Sharpe ME
Toxicol Pathol; 2018 Feb; 46(2):131-146. PubMed ID: 29471776
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical safety assessment of engineered T cell therapies.
Lebrec H; Maier CC; Maki K; Ponce R; Shenton J; Green S
Regul Toxicol Pharmacol; 2021 Dec; 127():105064. PubMed ID: 34656748
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice.
Dushenkov A; Jungsuwadee P
J Oncol Pharm Pract; 2019 Jul; 25(5):1217-1225. PubMed ID: 30890066
[TBL] [Abstract][Full Text] [Related]
4. [Next generation engineered T cells for cell therapy: from lymphoma to solid tumors].
Catros V
Med Sci (Paris); 2019 Apr; 35(4):316-326. PubMed ID: 31038109
[TBL] [Abstract][Full Text] [Related]
5. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
6. Overcoming key challenges in cancer immunotherapy with engineered T cells.
Arcangeli S; Mestermann K; Weber J; Bonini C; Casucci M; Hudecek M
Curr Opin Oncol; 2020 Sep; 32(5):398-407. PubMed ID: 32796230
[TBL] [Abstract][Full Text] [Related]
7. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials.
Arabi F; Torabi-Rahvar M; Shariati A; Ahmadbeigi N; Naderi M
Exp Cell Res; 2018 Aug; 369(1):1-10. PubMed ID: 29758187
[TBL] [Abstract][Full Text] [Related]
8. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.
Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J
J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789
[TBL] [Abstract][Full Text] [Related]
9. Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns.
Resetca D; Neschadim A; Medin JA
J Immunother; 2016 Sep; 39(7):249-59. PubMed ID: 27488725
[TBL] [Abstract][Full Text] [Related]
10. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
11. Managing the toxicities of CAR T-cell therapy.
Neelapu SS
Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535
[TBL] [Abstract][Full Text] [Related]
12. Unleash the power of the mighty T cells-basis of adoptive cellular therapy.
Sukari A; Abdallah N; Nagasaka M
Crit Rev Oncol Hematol; 2019 Apr; 136():1-12. PubMed ID: 30878123
[TBL] [Abstract][Full Text] [Related]
13. Tumor inflammation-associated neurotoxicity.
Mahdi J; Dietrich J; Straathof K; Roddie C; Scott BJ; Davidson TB; Prolo LM; Batchelor TT; Campen CJ; Davis KL; Gust J; Lim M; Majzner RG; Park JR; Partap S; Ramakrishna S; Richards R; Schultz L; Vitanza NA; Wang LD; Mackall CL; Monje M
Nat Med; 2023 Apr; 29(4):803-810. PubMed ID: 37024595
[TBL] [Abstract][Full Text] [Related]
14. Cellular therapy: Immune-related complications.
Oved JH; Barrett DM; Teachey DT
Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
17. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
18. Next Generation of Cancer Treatments: Chimeric Antigen Receptor T-Cell Therapy and Its Related Toxicities: A Review for Perioperative Physicians.
Echeverry G; Fischer GW; Mead E
Anesth Analg; 2019 Aug; 129(2):434-441. PubMed ID: 31124841
[TBL] [Abstract][Full Text] [Related]
19. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
Celichowski P; Turi M; Charvátová S; Radhakrishnan D; Feizi N; Chyra Z; Šimíček M; Jelínek T; Bago JR; Hájek R; Hrdinka M
J Transl Med; 2023 Mar; 21(1):197. PubMed ID: 36922828
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
